Abstract: According to an embodiment, a pitting corrosion propagation degree management system for a rotor dovetail in a rotor of a steam turbine for implanting a rotor blade of the steam turbine, the system comprises a display information generator configured to generate display information for displaying: past pitting corrosion propagation degree related information indicating information on a past pitting corrosion propagation degree of the rotor from the past to the present calculated based on measured information; and future pitting corrosion propagation degree related information indicating information on a future pitting corrosion propagation degree of the rotor dovetail calculated based on a future operation plan input through an input screen of a user interface and the past pitting corrosion propagation degree related information.

Abstract: A thinning amount managing apparatus in an embodiment for managing an amount of thinning of a first-stage rotor blade of a steam turbine caused by solid particles contained in working steam for working the steam turbine. The thinning amount managing apparatus includes a display information generation section configured to generate display information for displaying: past thinning amount related information indicating information on a past thinning amount of the first-stage rotor blade from the past to the present calculated based on measured information; and future thinning amount related information indicating information on a future thinning amount of the first-stage rotor blade calculated based on a future operating condition input via a user interface screen and the past thinning amount related information.

Abstract: The present invention provides endo-?-N-acetylglucosaminidase (Endo-Si) cloning from a strain belonging to Streptococcus iniae and a mutant enzyme thereof, a gene encoding the enzyme, a recombinant plasmid, a transformant obtained by transformation of a cell by the plasmid and use thereof, and a method for producing e.g., a sugar chain remodeled antibody using the enzyme. A polypeptide having an amino acid sequence at amino acid positions 34 to 928 in SEQ ID NO: 2 or an amino acid sequence having the same amino acid sequence except containing one or mutations at more amino acid positions selected from the group consisting of amino acids at position 241 (D241), 190 (T190), 311 (Q311) and 360 (E360), said polypeptide exhibiting a sugar chain hydrolysis activity and/or transglycosylation activity.

Abstract: An erosion amount managing apparatus in an embodiment includes a display information generation section configured to generate display information for displaying: past erosion amount related information indicating information on a past erosion amount of a rotor blade of a steam turbine from the past to the present calculated based on measured information; and future erosion amount related information indicating information on a future erosion amount of the rotor blade calculated based on a future operating condition input via a user interface screen and the past erosion amount related information.

Abstract: A steam turbine nozzle deformation amount managing apparatus in an embodiment includes a display information generation section configured to generate display information for displaying: past deformation amount related information indicating information on a past deformation amount of a nozzle of a steam turbine from the past to the present calculated based on measured information; and future deformation amount related information indicating information on a future deformation amount of the nozzle calculated based on a future operating condition input via a user interface screen and the past deformation amount related information.

Abstract: The present invention provides a novel endo-?-N-acetylglucosaminidase that is isolated from a fungus belonging to the genus Rhizomucor and is active under high-temperature conditions; various mutant enzymes thereof; genes encoding the enzymes; a recombinant plasmid; a transformant transformed with the plasmid; and the like.

Abstract: The present invention relates to a terpenoid derivative that has the ability to activate the Keap1/Nrf2/ARE signaling pathway and is excellent in anti-inflammatory action and cytoprotective action, and a sustained-release pharmaceutical composition effective for the treatment and prevention of a posterior eye disease caused by oxidative stress, comprising the terpenoid derivative as an active ingredient. The present invention provides a local administration-type sustained-release pharmaceutical composition for the treatment or prevention of a posterior eye disease, comprising the terpenoid derivative of the present invention as an active ingredient, wherein the sustained-release pharmaceutical composition maintains a pharmacological action thereof for 1 week or longer by the sustained release of the terpenoid derivative under physiological conditions and has a base material administrable to the vitreous body and a form administrable to the vitreous body.

Abstract: A stationary induction apparatus includes a cooled magnetic material ring disposed in an end portion of each winding and that can reduce an electromagnetic-mechanical force and improve reliability. The apparatus includes an iron core; a winding outside of the iron core; a plurality of iron core clamps that sandwich the winding from a longitudinal direction of the iron core; a magnetic material ring with a silicon steel plate wound outside of the iron core; a laminated magnetic material composite ring including an insulator on an outer circumference of the magnetic material ring; and a holding-and-cooling structure between the winding and the laminated magnetic material composite ring, in which a portion of the holding-and-cooling structure protruding from between the winding and the laminated magnetic material composite ring extends in the longitudinal direction, and the holding-and-cooling structure is a recess with respect to the winding and the laminated magnetic material composite ring.

Abstract: The present invention provides a novel endo-?-N-acetylglucosaminidase that is isolated from a fungus belonging to the genus Rhizomucor and is active under high-temperature conditions; various mutant enzymes thereof; genes encoding the enzymes; a recombinant plasmid; a transformant transformed with the plasmid; and the like.

Abstract: The present invention relates to a terpenoid derivative that has the ability to activate the Keap1/Nrf2/ARE signaling pathway and is excellent in anti-inflammatory action and cytoprotective action, and a sustained-release pharmaceutical composition effective for the treatment and prevention of a posterior eye disease caused by oxidative stress, comprising the terpenoid derivative as an active ingredient. The present invention provides a local administration-type sustained-release pharmaceutical composition for the treatment or prevention of a posterior eye disease, comprising the terpenoid derivative of the present invention as an active ingredient, wherein the sustained-release pharmaceutical composition maintains a pharmacological action thereof for 1 week or longer by the sustained release of the terpenoid derivative under physiological conditions and has a base material administrable to the vitreous body and a form administrable to the vitreous body.

Abstract: It is intended to provide a novel terpenoid derivative that exhibits anti-inflammatory action and a cytoprotective action by activating the Keap1/Nrf2/ARE signaling pathway.

Abstract: The present invention relates to a terpenoid derivative that has the ability to activate the Keap1/Nrf2/ARE signaling pathway and is excellent in anti-inflammatory action and cytoprotective action, and a sustained-release pharmaceutical composition effective for the treatment and prevention of a posterior eye disease caused by oxidative stress, comprising the terpenoid derivative as an active ingredient. The present invention provides a local administration-type sustained-release pharmaceutical composition for the treatment or prevention of a posterior eye disease, comprising the terpenoid derivative of the present invention as an active ingredient, wherein the sustained-release pharmaceutical composition maintains a pharmacological action thereof for 1 week or longer by the sustained release of the terpenoid derivative under physiological conditions and has a base material administrable to the vitreous body and a form administrable to the vitreous body.

Abstract: An object of the invention is to provide a stationary induction apparatus that includes an appropriately held and cooled magnetic material ring disposed in an end portion of each winding and that can reduce an electromagnetic-mechanical force and improve reliability.

Abstract: A stationary induction electric apparatus includes an iron core having legs of core and yokes of core; windings wound around the legs of core; coolant for cooling the windings; a cylindrical insulation structure that forms a flow of the coolant around the windings; baffle members alternately provided on the inner wall side and the outer wall side of the cylindrical insulation structure; and adjustment members for constricting the flow of the coolant. The adjustment members are provided on the same side of the respective baffle members and on the respective baffle members.

Abstract: There is provided a heat-sensitive transfer recording medium which is able to better suppress the occurrence of abnormal transfer during high-speed printing using a high-speed printer of sublimation transfer type and is able to improve transfer sensitivity in high-speed printing. The heat-sensitive transfer recording medium includes a base (10), a heat-resistant lubricating layer (20) formed on one surface of the base (10), an underlying layer (30) formed on the other surface of the base (10), and a dye layer (40) formed on a surface of the underlying layer (30), which is on the other side of a surface facing the base (10). In the heat-sensitive transfer recording medium, the underlying layer (30) has a major component that is a copolymer of polyester having a sulfonic group on a side chain and acrylic having at least one of a glycidyl group and a carboxyl group.

Abstract: There is provided a heat-sensitive transfer recording medium which is able to better suppress the occurrence of abnormal transfer during high-speed printing using a high-speed printer of sublimation transfer type and is able to improve transfer sensitivity in high-speed printing. The heat-sensitive transfer recording medium includes a base (10), a heat-resistant lubricating layer (20) formed on one surface of the base (10), an underlying layer (30) formed on the other surface of the base (10), and a dye layer (40) formed on a surface of the underlying layer (30), which is on the other side of a surface facing the base (10). In the heat-sensitive transfer recording medium, the underlying layer (30) has a major component that is a copolymer of polyester having a sulfonic group on a side chain and acrylic having at least one of a glycidyl group and a carboxyl group.

Abstract: It is intended to provide a novel terpenoid derivative that exhibits anti-inflammatory action and a cytoprotective action by activating the Keap1/Nrf2/ARE signaling pathway.

Abstract: While the whole weight of magnetic shields provided in a tank of a transformer is reduced, eddy current loss by magnetic flux leaked from a winding is reduced. A transformer is configured using an iron core having an iron core leg and an iron core yoke, windings wound around the iron core leg, a tank having the iron core and the windings therein, and a first magnetic shield and second magnetic shields formed by laminating silicon steel sheets inside the tank. The first magnetic shield is arranged opposite to the windings, the second magnetic shields are arranged between the first magnetic shield and the tank, and the first magnetic shield and the second magnetic shields are fixed to the tank by different support members.

Abstract: It is intended to provide a novel terpenoid derivative that exhibits anti-inflammatory action and a cytoprotective action by activating the Keap1/Nrf2/ARE signaling pathway.

Abstract: The present invention relates to a terpenoid derivative that has the ability to activate the Keap1/Nrf2/ARE signaling pathway and is excellent in anti-inflammatory action and cytoprotective action, and a sustained-release pharmaceutical composition effective for the treatment and prevention of a posterior eye disease caused by oxidative stress, comprising the terpenoid derivative as an active ingredient. The present invention provides a local administration-type sustained-release pharmaceutical composition for the treatment or prevention of a posterior eye disease, comprising the terpenoid derivative of the present invention as an active ingredient, wherein the sustained-release pharmaceutical composition maintains a pharmacological action thereof for 1 week or longer by the sustained release of the terpenoid derivative under physiological conditions and has a base material administrable to the vitreous body and a form administrable to the vitreous body.